Entries |
Document | Title | Date |
20080234353 | Formulations of Ramipril - The present invention relates to stable tablet formulations of ramipril, optionally in combination with a diuretic. | 09-25-2008 |
20080234354 | Methods And Compositions For Controlling Body Weight And Appetite - The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dislipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compositions of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent. | 09-25-2008 |
20080280966 | Hydroisoindoline Tachykinin Receptor Antagonists - The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety. | 11-13-2008 |
20080306133 | INTRANASAL ADMINISTRATION OF ASENAPINE AND PHARMACEUTICAL COMPOSITIONS THEREFOR - Asenapine or a pharmaceutically acceptable salt thereof can be administered intranasally, typically via an intranasal dosage formulation having a water-containing liquid carrier. | 12-11-2008 |
20080312307 | MAPK/ERK KINASE INHIBITORS - Compounds are provided for inhibition of MEK that comprise: | 12-18-2008 |
20080319043 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists - The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 12-25-2008 |
20090018181 | DRUG COMPOSITION FOR PREVENTION OR INHIBITION OF ADVANCE OF DIABETIC COMPLICATION - The present invention provides pharmaceutical compositions which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia. The present pharmaceutical composition is for administration before meal to prevent or inhibit the progression of diabetic complication, which comprises 5 to 45 mg, as a single dose, of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof (for example, mitiglinide calcium salt hydrate). And said compositions are extremely useful for prevention or inhibition of progression of, for example, diabetic microvascular complications and arteriosclerotic diseases, because the frequency of adverse drug reactions such as hypoglycemic symptoms and gastrointestinal disorders is low. | 01-15-2009 |
20090030062 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (IA) or a salt thereof: | 01-29-2009 |
20090048326 | Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor - The present invention relates to a compound of the formula (I) | 02-19-2009 |
20090076118 | DEUTERIUM-ENRICHED SAXAGLIPTIN - The present application describes deuterium-enriched saxagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076119 | DEUTERIUM-ENRICHED RAMIPRIL - The present application describes deuterium-enriched ramipril, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090203758 | Alpha Crystalline form of the Arginine salt of Perindopril, a Process for its Preparation and Pharmceutical Compositions Containing it. - α-crystalline form of the compound of formula (I): | 08-13-2009 |
20090209609 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents - The present invention is directed to novel compounds of Formula (I) | 08-20-2009 |
20090221664 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS - Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists (“MRA”), and at least one additional active ingredients selected from one or more β2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided. | 09-03-2009 |
20090270477 | POLYMORPHS OF A HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONIST - This application is directed to a novel polymorph of a hydroisoindoline tachykinin receptor antagonist having the following structural formula A. | 10-29-2009 |
20090306169 | Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors - The present invention provides the use of fused pyrrole carboxylic acids of formula (I) for the manufacture of a medicament to inhibit D-amino acid oxidase, particularly for the treatment of neurodegenerative and psychiatric disorders or diseases; certain compounds of formula I being novel, pharmaceutical compositions containing them, their use in medicine and methods of treatment using them are also disclosed. | 12-10-2009 |
20090312389 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 12-17-2009 |
20090318524 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS - The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals. | 12-24-2009 |
20100016400 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS - The present invention generally relates to muscarinic receptor antagonists, which are useful for treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to processes for preparing compounds described herein, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 01-21-2010 |
20100016401 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES - The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R | 01-21-2010 |
20100022612 | FUSED HETEROCYCLES - This invention provides fused heterocycles having the formula: | 01-28-2010 |
20100029738 | Bicyclic Tetrahydropyrrole Compounds - The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals. | 02-04-2010 |
20100029739 | Use of a combination of hypothermia inducing drugs - The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a combination of (1) vanilloid receptor agonists, capsaicinoids or capsaicinoid-like agonists reaching and binding to vanilloid receptors, and (2) cannabinoids or cannabimimetic agonists reaching and binding to cannabinoid receptors, thereby inducing hypothermia, thus benefiting patients suffering from illnesses characterized by tissue anoxia. | 02-04-2010 |
20100029740 | AZABICYCLIC COMPOUNDS AS SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS - Novel compounds of formula (I)′ and pharmaceutically acceptable salts, solvates and prodrugs thereof: | 02-04-2010 |
20100029741 | FUSED HETEROCYCLES - This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula: | 02-04-2010 |
20100035954 | ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS - Provided herein are acid addition salts of muscarinic receptor antagonists. Such acid addition salts are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided herein are processes for the preparation of acid addition salts, pharmaceutical compositions thereof, and methods of treating diseases mediated through muscarinic receptors. | 02-11-2010 |
20100035955 | Stabilised Composition Comprising ACE Inhibitors - A pharmaceutical composition comprising a) an ACE inhibitor prone to degradation or a pharmaceutically acceptable acid addition salt thereof; b) a stabilizing amount of an alkaline stabilizing agent; and c) pharmaceutically acceptable excipients wherein the composition further includes moisture controlling means. | 02-11-2010 |
20100041729 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS - The present invention provides dithiolopyrrolone compounds of the general formula I, and their salts, wherein A is sulfur or carbon, and R | 02-18-2010 |
20100099729 | NITRIC OXIDE DONOR COMPOUNDS - The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolismsdysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent. | 04-22-2010 |
20100137397 | Chemical Compounds - A compound of the formula (1) or a pharmaceutically-acceptable salt: possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as 2 diabetes. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described. | 06-03-2010 |
20100152269 | MODIFIED-RELEASE FORMULATIONS OF AZABICYCLO DERIVATIVES - The present invention discloses modified-release oral dosage forms of an azabicyclo derivative or its pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, N-oxides and polymorphs; and processes for the preparation thereof. The modified release formulation comprises an azabicyclo derivative, at least one rate-controlling polymer and at least one pharmaceutically acceptable excipient which provides therapeutically effective plasma levels of the active ingredient for a period of up to 24 hours. | 06-17-2010 |
20100160404 | NEW CRYSTALLINE FORMS OF PERINDOPRIL ERBUMINE - Disclosed are two new crystalline forms, δ and ε, of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardiovascular diseases, especially high blood pressure and heart failure. The ε crystalline form is obtained in the crystallisation of perindopril erbumine at from 30 to 45° C., preferably from 34 to 45° C., from MTBE containing from 1.5 to 2.5% (v/v) water; the crystallisation is advantageously carried out with stirring. If the water is then removed, advantageously by azeotropic distillation, preferably at from 35 to 37° C., and stirring is then continued for at least 15 h at from 30 to 45° C., preferably from 35 to 37° C., the ε crystalline form is converted to the δ crystalline form. The δ crystalline form can also be obtained by stirring the α or β crystalline form at from 33 to 38° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the δ crystalline form. The ε crystalline form can also be obtained by stirring the α or β crystalline form at from 28 to 35° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the ε crystalline form; or by stirring the α or β crystalline form at from 35 to 38° C. in tert.-butyl methyl ether containing from 1.5 to 2.0% (v/v) water. | 06-24-2010 |
20100173968 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide, ketone, and ester compounds prepared from certain azabicycloalkane carboxylic acids. The resulting compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, such as those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). | 07-08-2010 |
20100267798 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE - The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF). | 10-21-2010 |
20100267799 | Orodispersible pharmaceutical composition of perindopril - The invention relates to a solid orodispersible pharmaceutical composition of perindopril, characterised in that it comprises perindopril or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch. | 10-21-2010 |
20100298400 | SALTS OF PERINDOPRIL - The present invention relates to new salts of perindopril, particularly to a new calcium salt and new amine salts of perindopril, to a process for their preparation and to a pharmaceutical formulations containing the new salts. | 11-25-2010 |
20110003876 | Tetrahydroindoles Having Sphingosine-1-Phosphate Receptor Activity - Compounds are disclosed herein having the formula (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed. | 01-06-2011 |
20110124699 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present invention is directed to racemic 1-(3,4-dichlorophenyI)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1 .0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain. | 05-26-2011 |
20110130434 | MODIFIED RELEASE RAMIPRIL COMPOSITIONS AND USES THEREOF - The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril. | 06-02-2011 |
20110136886 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 06-09-2011 |
20110136887 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists - The invention relates to compounds of Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including antagonism of Prostaglandin EP4 receptor as a therapeutic treatment. | 06-09-2011 |
20110152340 | Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying subjects or patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments which comprise at least one polymorphic locus, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the invention are useful in phenotype correlations, medicine, and genetic analysis. | 06-23-2011 |
20110275687 | SAXAGLIPTIN INTERMEDIATES, SAXAGLIPTIN POLYMORPHS, AND PROCESSES FOR PREPARATION THEREOF - The invention provides Saxagliptin Schiff bases, polymorphs of Saxagliptin and (1S,3S,5S)-2-[(2S)-2-propan-2-ylideneamino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, processes for preparing Saxagliptin hydrates, and pharmaceutical compositions thereof. | 11-10-2011 |
20110313013 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE - Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided. | 12-22-2011 |
20120004275 | SCELETIUM EXTRACT AND USES THEREOF - A composition including as an active ingredient an extract of a plant of the family Mesembryanthemaceae with mesembrenol and mesembrenone as the two major alkaloids present. The invention also relates to the use of the composition as a PDE4 inhibitor and as a serotonin-uptake inhibitor, preferably applied in formulations for the use of the composition as a dual serotonin-uptake inhibitor and PDE4 inhibitor. The invention extends to compositions, such as pharmaceutical compositions or compositions used as dietary supplements, the total alkaloid content of which includes at least 80% (w/w) combined content of mesembrenol and mesembrenone, less than 5% (w/w) mesembrine, and at least 7% (w/w) mesembranol. | 01-05-2012 |
20120010260 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain. | 01-12-2012 |
20120065240 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present invention is directed to selective dopamine reuptake inhibitors, including (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome. | 03-15-2012 |
20120071536 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to N-[(2-aza-bicyclo[2.2.1]hex-1-yl)-aryl-methyl]-benzamide derivatives of the general formula (I) where: R is a hydrogen atom or a (C | 03-22-2012 |
20120083517 | POLYMORPHS OF SAXAGLIPTIN HYDROCHLORIDE AND PROCESSES FOR PREPARING THEM - The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride. | 04-05-2012 |
20120088808 | CRYSTAL FORMS OF SAXAGLIPTIN - The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride. | 04-12-2012 |
20120136038 | Novel Polymorphs Of Azabicyclohexane - The invention provides polymorphic crystalline forms of acid addition salts of (±)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 05-31-2012 |
20120190721 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain. | 07-26-2012 |
20120258994 | Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters - The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals. | 10-11-2012 |
20120302619 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 11-29-2012 |
20120316214 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Industrial synthesis process for, and crystalline form I of, the compound of formula (I): | 12-13-2012 |
20130123325 | USE OF BOCEPREVIR AND RELATED COMPOUNDS IN ATHEROSCLEROSIS, HEART FAILURE, RENAL DISEASES, LIVER DISEASES OR INFLAMMATORY DISEASES - The present invention relates to a compound of the formula I for use in the treatment of atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases. | 05-16-2013 |
20130150421 | COMBINATION OF 4-BENZAMIDE AND A NMDA RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}-benzamide of formula (I): | 06-13-2013 |
20130158091 | POLYMORPHS OF SAXAGLIPTIN HYDROCHLORIDE AND PROCESSES FOR PREPARING THEM - The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride. | 06-20-2013 |
20130253029 | NOVEL BICYCLIC COMPOUNDS - The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR). | 09-26-2013 |
20130345279 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE - The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 12-26-2013 |
20130345280 | Methods And Compositions Employing Bicifadine For Treating Disability Or Functional Impairment Associated With Acute Pain, Chronic Pain, Or Neuropathic Disorders - Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders. | 12-26-2013 |
20140039029 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS - The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals. | 02-06-2014 |
20140107175 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE - Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit re-uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided. | 04-17-2014 |
20140155453 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-{3[CIS-HEXAHYDROCYCLOPENT A[CjPYRROL-2( 1 H)-YLjPROPOXYj BENZAMI DE HYDROCHLORI DE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Medicinal products containing the crystalline form I of the compound of formula (I): | 06-05-2014 |
20140200252 | CRYSTAL FORMS OF SAXAGLIPTIN - The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride. | 07-17-2014 |
20140206740 | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters - The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse. | 07-24-2014 |
20140221449 | DIVIDABLE GALENICAL FORM ALLOWING MODIFIED RELEASE OF THE ACTIVE INGREDIENT - Dividable galenical form for the modified release of active ingredient, wherein the non-subdivided galenical form and a portion of said form obtained by subdivision have identical dissolution profiles. | 08-07-2014 |
20140235690 | ISCHEMIA/REPERFUSION PROTECTION COMPOSITIONS AND METHODS OF USING - The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery. | 08-21-2014 |
20140288142 | NITRIC OXIDE DONOR COMPOUNDS - The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent. | 09-25-2014 |
20150031737 | STABILIZED CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING GLICLAZIDE - The present invention provides a stabilized controlled-release pharmaceutical composition comprising gliclazide and sodium citrate as stabilizing agent; and process for the preparation of said pharmaceutical composition. | 01-29-2015 |
20150080447 | Sceletium Extract and Uses Thereof - A composition including as an active ingredient an extract of a plant of the family Mesembryanthemaceae with mesembrenol and mesembrenone as the two major alkaloids present. The invention also relates to the use of the composition as a PDE4 inhibitor and as a serotonin-uptake inhibitor, preferably applied in formulations for the use of the composition as a dual serotonin-uptake inhibitor and PDE4 inhibitor. The invention extends to compositions, such as pharmaceutical compositions or compositions used as dietary supplements, the total alkaloid content of which includes at least 80% (w/w) combined content of mesembrenol and mesembrenone, less than 5% (w/w) mesembrine, and at least 7% (w/w) mesembranol. | 03-19-2015 |
20150080448 | COMBINATION OF 4- BENZAMIDE AND A NMDA RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}-benzamide of formula (I): | 03-19-2015 |
20150087686 | CRYSTALLINE FORMS OF SAXAGLIPTIN - It comprises a cocrystal of saxagliptin hydrochloride and a compound selected from the group consisting of saxagliptin, glycolic acid, malonic acid, and urea; or a solvate thereof, or a hydrate thereof. It also comprises a salt of saxagliptin with glycolic acid 1:1 hydrate. It also comprises their preparation processes, as well as their use as antidiabetics. | 03-26-2015 |
20150148399 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 05-28-2015 |
20160008324 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE | 01-14-2016 |
20160051513 | USE OF 4-BENZAMIDE IN THE TREATMENT OF NEUROPATHIC PAIN - Use of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): | 02-25-2016 |
20160158196 | A MODIFIED-RELEASE ORAL PHARMACEUTICAL FORMULATION CONTAINING GLICLAZIDE - Sustained-release Gliclazide tablets devoid of calcium phosphate dibasic, and containing only soluble excipients. The mixing of two high viscosity HPMC with a low viscosity one allows to obtain releases similar to those of the reference products on the market, and it shows also a certain pH dependence. | 06-09-2016 |
20160158197 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 06-09-2016 |
20160199347 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | 07-14-2016 |